525 related articles for article (PubMed ID: 25363661)
1. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
3. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
4. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet.
Lussier DM; Woolf EC; Johnson JL; Brooks KS; Blattman JN; Scheck AC
BMC Cancer; 2016 May; 16():310. PubMed ID: 27178315
[TBL] [Abstract][Full Text] [Related]
7. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
8. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.
Wallenfriedman MA; Conrad JA; DelaBarre L; Graupman PC; Lee G; Garwood M; Gregerson DS; Jean WC; Hall WA; Low WC
J Neurosurg; 1999 Jun; 90(6):1064-71. PubMed ID: 10350253
[TBL] [Abstract][Full Text] [Related]
9. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
10. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
11. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
13. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
14. Immunotreatment in patients with glioblastoma multiforme--a histopathological evaluation of reactive and inflammatory changes.
Persson A; Skagerberg G; Salford LG; Englund E;
Clin Neuropathol; 2005; 24(5):201-8. PubMed ID: 16167543
[TBL] [Abstract][Full Text] [Related]
15. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
16. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
17. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W
Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy targeting glioma stem cells--insights and perspectives.
Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
[TBL] [Abstract][Full Text] [Related]
19. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
